An Update on Vaccines Against Shigella

Overview

Journal Ther Adv Vaccines

Publisher Sage Publications

Date 2014 Apr 24

PMID 24757519

Citations 26

Authors

Shai Ashkenazi

Dani Cohen

Affiliations

Soon will be listed here.

Abstract

Despite intensive research efforts for more than 60 years, utilizing diverse vaccine strategies, a safe and efficacious vaccine against shigellosis is not available yet. We are currently witnessing innovative approaches based on elucidation of the virulence mechanisms of Shigella, understanding the immune response to the pathogen and progress in molecular technology for developing Shigella vaccines. It is hoped that these will lead to a licensed effective Shigella vaccine to protect humans against the significant worldwide morbidity and mortality caused by this microorganism.

Citing Articles

Safety and Tolerability of ShigActive™, a spp. Targeting Bacteriophage Preparation, in a Phase 1 Randomized, Double-Blind, Controlled Clinical Trial.

Chen W, Woolston J, Grant-Beurmann S, Robinson C, Bansal G, Nkeze J Antibiotics (Basel). 2024; 13(9).

PMID: 39335031 PMC: 11429168. DOI: 10.3390/antibiotics13090858.

A rhesus macaque intragastric challenge model for evaluating the safety, immunogenicity, and efficacy of live-attenuated 1 vaccine candidates.

Ruamsap N, Imerbsin R, Khanijou P, Gonwong S, Oransathit W, Barnoy S Front Microbiol. 2024; 15:1454338.

PMID: 39309527 PMC: 11413625. DOI: 10.3389/fmicb.2024.1454338.

Investigation of the vaccine potential of an designed FepA peptide vaccine against in mice model.

Ali M, Mahmud S, Faruque M, Hossain M, Hossain M, Kibria K Vaccine X. 2024; 18:100493.

PMID: 38812954 PMC: 11134883. DOI: 10.1016/j.jvacx.2024.100493.

The Potential Role of Vaccines in Preventing Antimicrobial Resistance (AMR): An Update and Future Perspectives.

Costanzo V, Roviello G Vaccines (Basel). 2023; 11(2).

PMID: 36851210 PMC: 9962013. DOI: 10.3390/vaccines11020333.

Detoxified O-Specific Polysaccharide (O-SP)-Protein Conjugates: Emerging Approach in the Vaccine Development Scene.

Cohen D, Meron-Sudai S, Bialik A, Asato V, Ashkenazi S Vaccines (Basel). 2022; 10(5).

PMID: 35632431 PMC: 9145086. DOI: 10.3390/vaccines10050675.

References

Orr N, Katz D, Atsmon J, Radu P, Yavzori M, Halperin T . Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers. Infect Immun. 2005; 73(12):8027-32. PMC: 1307051. DOI: 10.1128/IAI.73.12.8027-8032.2005. View

Guerrero L, Calva J, Morrow A, Velazquez F, Tuz-Dzib F, Lopez-Vidal Y . Asymptomatic Shigella infections in a cohort of Mexican children younger than two years of age. Pediatr Infect Dis J. 1994; 13(7):597-602. DOI: 10.1097/00006454-199407000-00003. View

Ashkenazi S . Shigella infections in children: new insights. Semin Pediatr Infect Dis. 2004; 15(4):246-52. DOI: 10.1053/j.spid.2004.07.005. View

Venkatesan M, Fernandez-Prada C, Buysse J, Formal S, Hale T . Virulence phenotype and genetic characteristics of the T32-ISTRATI Shigella flexneri 2a vaccine strain. Vaccine. 1991; 9(5):358-63. DOI: 10.1016/0264-410x(91)90064-d. View

Shiferaw B, Solghan S, Palmer A, Joyce K, Barzilay E, Krueger A . Antimicrobial susceptibility patterns of Shigella isolates in Foodborne Diseases Active Surveillance Network (FoodNet) sites, 2000-2010. Clin Infect Dis. 2012; 54 Suppl 5:S458-63. DOI: 10.1093/cid/cis230. View

Levenson V, Mallett C, Hale T . Protection against local Shigella sonnei infection in mice by parenteral immunization with a nucleoprotein subcellular vaccine. Infect Immun. 1995; 63(7):2762-5. PMC: 173369. DOI: 10.1128/iai.63.7.2762-2765.1995. View

Goren A, Freier S, Passwell J . Lethal toxic encephalopathy due to childhood shigellosis in a developed country. Pediatrics. 1992; 89(6 Pt 2):1189-93. View

Riddle M, Kaminski R, Williams C, Porter C, Baqar S, Kordis A . Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine. Vaccine. 2011; 29(40):7009-19. DOI: 10.1016/j.vaccine.2011.07.033. View

Kotloff K, Winickoff J, Ivanoff B, Clemens J, Swerdlow D, Sansonetti P . Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ. 1999; 77(8):651-66. PMC: 2557719. View

10.

Martinez-Becerra F, Kissmann J, Diaz-McNair J, Choudhari S, Quick A, Mellado-Sanchez G . Broadly protective Shigella vaccine based on type III secretion apparatus proteins. Infect Immun. 2011; 80(3):1222-31. PMC: 3294653. DOI: 10.1128/IAI.06174-11. View

11.

Cohen D, Green M, Block C, Slepon R, Ofek I . Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis. J Clin Microbiol. 1991; 29(2):386-9. PMC: 269772. DOI: 10.1128/jcm.29.2.386-389.1991. View

12.

Khan M . Interruption of shigellosis by hand washing. Trans R Soc Trop Med Hyg. 1982; 76(2):164-8. DOI: 10.1016/0035-9203(82)90266-8. View

13.

Phalipon A, Tanguy M, Grandjean C, Guerreiro C, Belot F, Cohen D . A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection. J Immunol. 2009; 182(4):2241-7. DOI: 10.4049/jimmunol.0803141. View

14.

Passwell J, Freier S, Shor R, Farzam N, Block C, Lison M . Shigella lipopolysaccharide antibodies in pediatric populations. Pediatr Infect Dis J. 1995; 14(10):859-65. DOI: 10.1097/00006454-199510000-00008. View

15.

Prince Christopher R H , David K, John S, Sankarapandian V . Antibiotic therapy for Shigella dysentery. Cochrane Database Syst Rev. 2010; (1):CD006784. DOI: 10.1002/14651858.CD006784.pub3. View

16.

Martin T, Habbick B, Nyssen J . Shigellosis with bacteremia: a report of two cases and a review of the literature. Pediatr Infect Dis. 1983; 2(1):21-6. View

17.

Cohen D, Ashkenazi S, Green M, Yavzori M, Orr N, Slepon R . Safety and immunogenicity of the oral E. coli K12-S. flexneri 2a vaccine (EcSf2a-2) among Israeli soldiers. Vaccine. 1994; 12(15):1436-42. DOI: 10.1016/0264-410x(94)90153-8. View

18.

McKenzie R, Walker R, Nabors G, Van De Verg L, Carpenter C, Gomes G . Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial. Vaccine. 2005; 24(18):3735-45. DOI: 10.1016/j.vaccine.2005.07.014. View

19.

MEITERT T, Pencu E, Ciudin L, Tonciu M . Vaccine strain Sh. flexneri T32-Istrati. Studies in animals and in volunteers. Antidysentery immunoprophylaxis and immunotherapy by live vaccine Vadizen (Sh. flexneri T32-Istrati). Arch Roum Pathol Exp Microbiol. 1984; 43(3-4):251-78. View

20.

Ashkenazi S, Dinari G, Zevulunov A, Nitzan M . Convulsions in childhood shigellosis. Clinical and laboratory features in 153 children. Am J Dis Child. 1987; 141(2):208-10. DOI: 10.1001/archpedi.1987.04460020098036. View